Zoetis (ZTS) Accumulated Expenses (2012 - 2026)
Zoetis (ZTS) posted quarterly Accumulated Expenses of $239.0 million for Q1 2026, down 17.87% year-over-year from $291.0 million in Q1 2025, and down 40.4% quarter-over-quarter from $401.0 million in Q4 2025.
Zoetis (ZTS) Accumulated Expenses (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Accumulated Expenses for 15 consecutive years, with $239.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 17.87% year-over-year to $239.0 million; the TTM figure through Mar 2026 stood at $239.0 million (down 17.87% YoY), while the FY2025 annual figure was $401.0 million, down 46.25% from the prior year.
- Accumulated Expenses declined to $239.0 million in Q1 2026 per ZTS's latest filing, from $401.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $746.0 million in Q4 2024 and bottomed at $232.0 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $340.5 million across 5 years, with a median of $284.0 million in 2023.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 95.29% — and 2025, when it tumbled 46.25%.
- Zoetis' Accumulated Expenses stood at $682.0 million in 2022, then slumped by 43.99% to $382.0 million in 2023, then soared by 95.29% to $746.0 million in 2024, then sank by 46.25% to $401.0 million in 2025, then tumbled by 40.4% to $239.0 million in 2026.
- Business Quant data shows ZTS's Accumulated Expenses at $239.0 million in Q1 2026, $401.0 million in Q4 2025, and $337.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269.00 Mn |
| Mar 31, 2026 | 239.00 Mn |
| Dec 31, 2025 | 401.00 Mn |
| Sep 30, 2025 | 337.00 Mn |
| Jun 30, 2025 | 293.00 Mn |
| Mar 31, 2025 | 291.00 Mn |
| Dec 31, 2024 | 746.00 Mn |
| Sep 30, 2024 | 335.00 Mn |
| Jun 30, 2024 | 276.00 Mn |
| Mar 31, 2024 | 272.00 Mn |
| Dec 31, 2023 | 382.00 Mn |
| Sep 30, 2023 | 284.00 Mn |
| Jun 30, 2023 | 247.00 Mn |
| Mar 31, 2023 | 232.00 Mn |
| Dec 31, 2022 | 682.00 Mn |
| Sep 30, 2022 | 257.00 Mn |
| Jun 30, 2022 | 237.00 Mn |
| Mar 31, 2022 | 278.00 Mn |
| Dec 31, 2021 | 710.00 Mn |
| Sep 30, 2021 | 314.00 Mn |